49 in-depth guides in this cluster
Product-market fit for MedTech is not SaaS PMF. You cannot test the technology with customers, but you can verify the market. Here is how to find PMF before MDR eats runway.
In MedTech, you need PMF before regulation, but you also need regulation before you can ship. The paradox breaks most first-time founders. Here is how to resolve it.
Before you spend a euro on MDR, verify the market for your MedTech idea. Here is the pre-regulatory validation sequence Felix uses with every MedTech founder.
Pick one narrow market. Get CE marking for that specific intended purpose. Expand later. Here is the beachhead strategy adapted for regulated MedTech startups.
Some MedTech products can launch as wellness first and later transition to medical device status. Here is when the strategy works, when it does not, and the legal boundary.
Your intended purpose must be specific enough for classification but not so narrow it boxes you in. Here is how to write one that satisfies both.
Customer discovery in MedTech is not 'talk to users.' It is interviewing clinicians, patients, and hospital buyers with different questions for each. Here is how to do it right.
The champion who loves your device is not the person who signs the purchase order. Here is how to map the full decision-making unit for MedTech B2B sales.
The MedTech value chain runs from manufacturer through importer, distributor, hospital procurement, clinician, payer, and patient. Here is how MDR maps to each.
How hospital procurement actually works under MEAT criteria and value analysis committees, and why CE mark is necessary but not sufficient to win deals.
How B2B hospital sales and direct-to-patient MedTech differ under MDR on lay-user IFU duties, distance selling rules, reimbursement, and evidence.
MedTech revenue models are constrained by reimbursement, procurement cycles, and device class. Here is how to choose the right one.
The razor-and-blade revenue model works well for MedTech when single-use consumables carry the margin. Here is how to structure it under MDR.
How subscription pricing, feature flags, and tiered plans interact with MDR Annex VIII Rule 11, significant change rules, and MDCG 2019-11 Rev.1.
Competitive analysis for MedTech is not a grid of feature checkmarks. It is understanding how the DMU actually compares options and where your device creates real asymmetry.
Two-phase development is a startup strategy, not just a regulatory tactic. Phase 1 proves the product is worth building. Phase 2 makes it certifiable. Here is the strategic case.
What a minimum viable product actually means for MDR medical devices, what can ship without CE, and how to avoid locking intended purpose too early.
How to sequence clinical data, technical documentation, QMS and CER work during the pre-launch phase so a notified body review does not sink your timeline.
How to write a MedTech business plan that works for both investors and regulators — dual-audience structure, intended purpose, classification, and CER strategy.
The CE mark is the start of GTM, not the end. Here is the MedTech GTM playbook from certification to first paying hospital.
Pricing strategy medical devices Europe: cost structure, margin floors, payer constraints, country negotiation, and why low pricing kills MedTech.
HTA market access pricing medical device: how Joint Clinical Assessments, national HTA bodies and MDR evidence overlap shape your launch plan.
KOL strategy MedTech startups: identify clinical champions, structure advisory relationships, and respect MDR Article 7 promotional rules.
Evidence generation strategy MedTech: one integrated stack that satisfies MDR Article 61, PMS, HTA bodies, and payers without running two trials.
Pivoting in MedTech is more expensive than in SaaS because the regulatory work is partly device-specific. Here is when to pivot and how to keep regulatory value.
The ten most common reasons MedTech startups die — each with the specific failure pattern Tibor and Felix have watched repeat across dozens of companies.
A 12-month CE marking timeline for a SaMD startup is achievable with the right discipline. Here is the anonymised case study and the choices that made it work.
Anonymized case study of a hardware MedTech startup that ran out of money during MDR conformity assessment, and what they should have done.
Anonymized case study of pivoting from wellness to medical device: how a beachhead strategy and a disciplined intended purpose rewrite enabled CE marking.
AI diagnostics startup failed Notified Body audit: a composite teaching case on intended purpose drift, weak clinical evidence, and model documentation gaps.
Spinning a university research project into a CE-marked medical device in 24 months is possible but unusual. Here is the anonymised case study.
Real MedTech timelines are 2-5x what founders plan for. Here is the honest version — phase by phase — of what actually takes how long from idea to revenue.
How long until a MedTech startup sees its first euro? Realistic revenue timelines by class, hidden delays, and what actually shortens the path.
The 14 milestones every MedTech startup hits from idea to market, what each unlocks for funding and hiring, and how long they realistically take.
Regulatory strategy is not separate from business strategy — it is a dimension of it. Here is how to align them so MDR work accelerates rather than drains the business.
The DIY vs expert regulatory decision is not a single choice — it's a series of scoped decisions. Here is the framework for each.
Knowing when to hire an MDR consultant is as important as knowing how to evaluate one. Here are the concrete signs that mean it is time.
Subtract to Ship is the discipline of removing work that does not earn its place. Here is how to apply it specifically to MedTech startup operations.
How MedTech startups can borrow the regulatory rigor of big incumbents without inheriting their bloated committees, ceremony, and paperwork-for-paperwork.
Platform vs point solution for MedTech startups: how intended purpose, classification, and technical file structure shape the right strategic choice.
Open innovation MedTech hospitals research: structuring collaborations under MDR Articles 62-82, who owns data and IP, and where manufacturer duty stays.
IP strategy for MedTech startups: patents, trade secrets, freedom to operate, and how technical file confidentiality interacts with EUDAMED transparency.
MedTech startup metrics beyond revenue: the regulatory KPIs, PMS signals and NB interaction data that actually predict whether you will ship and scale.
MedTech startup ecosystem Europe 2026: where the clusters are, how to read accelerators and public funding, and what to look for before joining a hub.
The complete MedTech startup playbook for 2027: the end-to-end path from idea to CE marking, with every decision point, cost bracket, and time window.
Five stages most MedTech founders move through on the MDR path: denial, shock, anger, bargaining, acceptance — and what to do at each one.
How MDR certification becomes a durable competitive moat for MedTech startups — and how to position it correctly in fundraising and strategy.
A subtraction audit for MedTech: cut every feature that does not improve experience, speed, revenue, or regulatory necessity before it eats your budget.
The intended purpose trap is the number one MedTech startup killer. Why wrong Zweckbestimmung under MDR Article 2(12) cascades into class, claims, and CER scope.